Bicara Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Bicara Therapeutics Inc. (BCAX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $90.40 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-03-30
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $90.40M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2025-12-31 | $90.40M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |